Core Viewpoint - Luye Pharma Group Limited has completed the issuance of 1.5 million exchangeable preferred shares, which can be exchanged for existing shares of Boan Biotechnology, representing approximately 16.15% of Boan's total issued shares [1] Group 1 - The issuer, Luye Geneora Holding Limited, a wholly-owned subsidiary of the company, has allocated and issued 1.5 million exchangeable preferred shares to the subscribers [1] - The exchangeable preferred shares can be converted into shares of Boan Biotechnology without the issuance of any new shares by Boan [1] - Based on the initial exchange price of HKD 11.718, the total number of Boan shares deliverable upon the exchange of all preferred shares is up to 100,486,431 shares [1]

智通财经APP讯，绿叶制药(02186)发布公告，于2025年12月12日，根据认购协议的条款，可交换优先股 的发行已完成。发行人Luye Geneora Holding Limited(本公司的全资附属公司)已向认购人配发及发行150 万股可交换优先股。 该等可交换优先股可交换为本集团所持博安生物的现有股份，并不涉及博安生物发行任何新股份。按初 始交换价11.718港元计算，于交换所有可交换优先股后可交付的博安生物股份总数最高为100,486,431 股，截至本公告日期，占博安生物已发行股份总数约16.15%。 ...

格隆汇12月12日丨绿叶制药(02186.HK)公告，于2025年12月12日，根据认购协议之条款，可交换优先股 之发行已完成。据此，发行人Luye Geneora Holding Limited(公司之全资附属公司)已向认购人Bluebell Asset Holding Ltd.配发及发行150万股可交换优先股。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 之全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何 責 任。 LUYE PHARMA GROUP LTD. 綠葉製藥集團有限公司 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：02186） 須予披露交易 本公司全資附屬公司完成發行可交換優先股 發行可交換優先股 於2025年12月12日，根 據 認 購 協 議 之 條 款，可 交 換 優 先 股 之 發 行 已 完 成。據 此，發 行 人（本 公 司 之 全 資 附 屬 公 司）已向認購人配發及發行1,500,000股可交 換 優 先 股。 該等可交換優先股可交換為本集團所持博安生物之現有股份，並不涉及博安 生 物 發 行 任 何 新 股 份。按 初 始 交 換 價11.718港 元 計 算，於 交 換 所 有 可 交 換 優 先股後可交付的博安生物股份總數最高為100,486,431股，截 至 本 公 告 日 期， 佔博安生物 ...

Core Viewpoint - The announcement of the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the first edition of the Commercial Health Insurance Innovative Drug Catalog, highlights the inclusion of several new drugs from various pharmaceutical companies, indicating potential growth opportunities in the healthcare sector [1][5]. Group 1: New Drug Inclusions - Green Leaf Pharmaceutical has five new products included in the 2025 National Medical Insurance Drug Catalog or the Commercial Health Insurance Innovative Drug Catalog, including MiMeiXin and RuiBaiLai, marking significant advancements in pain management and treatment options [2][6]. - RoXin Pharmaceutical's core innovative drug, TaiXinZan, has been included in the 2025 National Medical Insurance Drug Catalog, achieving full coverage for its approved indications [6][7]. - Dongcheng Pharmaceutical's product, Technetium-99m labeled Tetrakis, has been successfully included in the National Medical Insurance Drug Catalog, filling a gap in the market for myocardial perfusion imaging agents [8][9]. Group 2: Stock Performance - As of December 8, Green Leaf Pharmaceutical's stock price reached 3.05 yuan, reflecting a 40.55% increase since the beginning of the year [2][6]. - RoXin Pharmaceutical's stock price was 5.18 yuan as of December 9, showing a 35.6% increase year-to-date [7][8]. - Dongcheng Pharmaceutical's stock price was 14.66 yuan as of December 9, with a year-to-date increase of 20.26% [8][9]. - Rongchang Bio's stock price reached 85.29 yuan as of December 9, marking a significant increase of 183.25% since the start of the year [9]. Group 3: Innovative Treatments - MiMeiXin is noted as the first oral naloxone formulation in China for pain management, while RuiBaiLai offers a unique long-acting injection regimen [2][6]. - TaiXinZan has demonstrated superior efficacy in eradicating Helicobacter pylori compared to traditional treatments, showcasing its innovative therapeutic mechanism [7]. - HaiPuYi, a product from LuNan Pharmaceutical, has been included in the first edition of the Commercial Health Insurance Innovative Drug Catalog, addressing a critical shortage in the treatment of phenylketonuria [9].

该五款新产品包括：米美欣®(羟考酮纳洛酮缓释片)、瑞百莱®(棕榈酸帕利哌酮注射液(Ⅱ))首次纳入国 家医保药品目录；赞必佳®(注射用芦比替定)成功入选商保创新药目录；百拓维®(注射用戈舍瑞林微 球)、瑞可妥®(注射用利培酮微球(Ⅱ))顺利续约，继续被纳入国家医保药品目录。 本文源自：智通财经网 智通财经获悉，绿叶制药(02186)涨近3%，截至发稿，涨2.66%，报3.09港元，成交额837.51万港元。 消息面上，12月7日，绿叶制药发布公告，集团共有五款新产品成功纳入由国家医疗保障局发布的《国 家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(国家医保药品目录)或《商业健康保险创新 药品目录(2025年)》(商保创新药目录)。 ...

绿叶制药(02186)涨近3%，截至发稿，涨2.66%，报3.09港元，成交额837.51万港元。 消息面上，12月7日，绿叶制药发布公告，集团共有五款新产品成功纳入由国家医疗保障局发布的《国 家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(国家医保药品目录)或《商业健康保险创新 药品目录(2025年)》(商保创新药目录)。 该五款新产品包括：米美欣®(羟考酮纳洛酮缓释片)、瑞百莱®(棕榈酸帕利哌酮注射液(Ⅱ))首次纳入国 家医保药品目录；赞必佳®(注射用芦比替定)成功入选商保创新药目录；百拓维®(注射用戈舍瑞林微 球)、瑞可妥®(注射用利培酮微球(Ⅱ))顺利续约，继续被纳入国家医保药品目录。 ...

Core Viewpoint - Green Leaf Pharmaceutical (02186) saw a nearly 3% increase in stock price, currently at HKD 3.09, with a trading volume of HKD 8.3751 million, following the announcement of five new products being included in the National Medical Insurance Catalog for 2025 and the Commercial Health Insurance Innovative Drug Catalog for 2025 [1] Group 1 - Five new products from Green Leaf Pharmaceutical have been successfully included in the National Medical Insurance Catalog and the Commercial Health Insurance Innovative Drug Catalog for 2025 [1] - The new products include: - Mimesin (Oxycodone Naloxone Extended-Release Tablets) and Ruibailai (Paliperidone Palmitate Injection (II)) which are newly included in the National Medical Insurance Catalog [1] - Zanbija (Injectable Lurbinectedin) which has been successfully included in the Commercial Health Insurance Innovative Drug Catalog [1] - Baituowei (Injectable Goserelin Microspheres) and Ruiketuo (Injectable Risperidone Microspheres (II)) which have successfully renewed their inclusion in the National Medical Insurance Catalog [1]

每经AI快讯，绿叶制药(02186.HK)涨近3%，截至发稿涨2.66%，报3.09港元，成交额837.51万港元。 （文章来源：每日经济新闻） ...

智通财经APP获悉，绿叶制药(02186)涨近3%，截至发稿，涨2.66%，报3.09港元，成交额837.51万港 元。 该五款新产品包括：米美欣(羟考酮纳洛酮缓释片)、瑞百莱(棕榈酸帕利哌酮注射液(Ⅱ))首次纳入国家医 保药品目录；赞必佳(注射用芦比替定)成功入选商保创新药目录；百拓维®(注射用戈舍瑞林微球)、瑞 可妥(注射用利培酮微球(Ⅱ))顺利续约，继续被纳入国家医保药品目录。 消息面上，12月7日，绿叶制药发布公告，集团共有五款新产品成功纳入由国家医疗保障局发布的《国 家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(国家医保药品目录)或《商业健康保险创新 药品目录(2025年)》(商保创新药目录)。 ...